Education
About Us
Working with TipRanks
Follow Us
Coherus Biosciences (CHRS)
NASDAQ:CHRS
Total Valuation
Coherus Biosciences has a market cap or net worth of $107.77M. The enterprise value is $331.94M.
Market Cap$107.77M
Enterprise Value$331.94M
Share Statistics
Coherus Biosciences has 115,896,850 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding115,896,850
Owned by Insiders1.22%
Owned by Institutions0.10%
Financial Efficiency
Coherus Biosciences’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -66.77%.
Return on Equity (ROE)-0.22
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)-66.77%
Return on Capital Employed (ROCE)-0.67
Revenue Per Employee1.17M
Profits Per Employee125.03K
Employee Count228
Asset Turnover0.60
Inventory Turnover1.68
Valuation Ratios
The current PE Ratio of Coherus Biosciences is 5.55. Coherus Biosciences’s PEG ratio is -0.05.
PE Ratio5.55
PS Ratio0.00
PB Ratio-1.20
Price to Fair Value-1.20
Price to FCF-7.73
Price to Operating Cash Flow-7.73
PEG Ratio-0.05
Income Statement
In the last 12 months, Coherus Biosciences had revenue of 266.96M and earned 28.51M in profits. Earnings per share was 0.25.
Revenue266.96M
Gross Profit149.41M
Operating Income-111.67M
Pretax Income28.51M
Net Income28.51M
EBITDA60.94M
Earnings Per Share (EPS)0.25
Cash Flow
In the last 12 months, operating cash flow was -20.44M and capital expenditures 0.00, giving a free cash flow of -20.44M billion.
Operating Cash Flow-20.44M
Free Cash Flow-20.44M
Free Cash Flow per Share-0.18
Dividends & Yields
Coherus Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.64
52-Week Price Change-53.30%
50-Day Moving Average0.96
200-Day Moving Average1.16
Relative Strength Index (RSI)50.09
Average Volume (3m)1.78M
Important Dates
Coherus Biosciences upcoming earnings date is May 12, 2025, TBA Not Confirmed.
Last Earnings DateMar 10, 2025
Next Earnings DateMay 12, 2025
Ex-Dividend Date―
Financial Position
Coherus Biosciences as a current ratio of 1.21, with Debt / Equity ratio of -204.49%
Current Ratio1.21
Quick Ratio0.96
Debt to Market Cap1.46
Net Debt to EBITDA1.73
Interest Coverage Ratio-4.11
Taxes
In the past 12 months, Coherus Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Coherus Biosciences EV to EBITDA ratio is 4.33, with an EV/FCF ratio of -12.90.
EV to Sales0.99
EV to EBITDA4.33
EV to Free Cash Flow-12.90
EV to Operating Cash Flow-12.90
Balance Sheet
Coherus Biosciences has $125.99M in cash and marketable securities with ― in debt, giving a net cash position of $143.92M billion.
Cash & Marketable Securities$125.99M
Total Debt―
Net Cash$143.92M
Net Cash Per Share$1.24
Tangible Book Value Per Share-$1.62
Margins
Gross margin is 54.96%, with operating margin of -41.83%, and net profit margin of 10.68%.
Gross Margin54.96%
Operating Margin-41.83%
Pretax Margin10.68%
Net Profit Margin10.68%
EBITDA Margin22.83%
EBIT Margin20.85%
Analyst Forecast
The average price target for Coherus Biosciences is $5.02, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$5.02
Price Target Upside407.07% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast3.78%
EPS Growth Forecast―